New shot aims to reverse cancer wasting

NCT ID NCT07519564

Recruiting now Symptom relief Sponsor: Kexing Biopharm Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain weight and muscle.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GB18 (a monoclonal antibody)
What this could lead to: If it works, this could lead to a treatment that helps cancer patients with cachexia regain appetite and weight, improving their quality of life.
What could go wrong: This is a very early Phase 1 trial with only 18-36 people, so it's too soon to know if it works. The main goal is safety, not effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer breast cancer Cachexia colorectal cancer esophageal cancer gastric cancer malignant pancreatic neoplasm neoplasm non-small cell lung carcinoma ovarian cancer prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CACHEXIA; CANCER

Contacts and locations

Locations

Beijing GoBroad Hospital
RECRUITING

Beijing, Beijing Municipality, 102200, China
Peking University Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.